


**miREIA**  
miRNA Enzyme Immunoassay



# microRNAs for Diagnostics in Colorectal cancer



Colorectal cancer (CRC) is the third most prevalent cancer in the world. The screening and diagnosis of CRC currently relies heavily on invasive endoscopic techniques as well as imaging and antigen detection tools. More accessible and reliable biomarkers are necessary for early detection and prediction of CRC in order to expedite treatment and improve patient outcomes.

Many studies have indicated, that circulating miRNAs are characterized by high sensitivity and specificity to CRC and, moreover, they are very stable in body fluids. Therefore we believe that miRNAs are very promising non-invasive biomarkers and new discoveries in their detection and quantification will facilitate their translation to clinical practice.



## QUANTITATIVE

- Sensitive
- Absolute quantification



## ROBUST

- ELISA platform
- No reverse transcription
- No amplification



## FAST

- 2-hours assay



## AFFORDABLE

- Low cost per sample
- No special equipment

# Circulating microRNAs associated with the diagnosis of CRC

Colorectal cancer				
miRNA	Direction of alteration	Value of biomarker	Sample	References
let-7a-5p	Decreased	Diagnostic	Plasma	1
let-7f-5p	Decreased	Diagnostic	Plasma	1
miR-7	Increased	Diagnostic	Plasma	2
miR-9b	Decreased	Diagnostic	Serum	3
miR-17-3p	Increased	Diagnostic/ Prognostic	Serum	4
miR-17-3p	No difference		Serum	5
miR-19a-3p	Increased	Diagnostic	Serum	6
miR-20a	Increased	Diagnostic	Plasma	7
miR-21-5p	Increased	Diagnostic	Serum/whole blood/serum	6, 8, 9
miR-23a-3p	Increased	Diagnostic/ Prognostic	Serum	10
miR-24	Decreased	Diagnostic	Plasma	11
miR-26a-5p	Decreased	Diagnostic	Plasma	12
miR-27a-3p	Increased	Diagnostic	Serum	10
miR-29a	Increased	Diagnostic	Serum/plasma/ serum	9, 13, 14
miR-29a	No difference		Serum/plasma	5, 7
miR-29b	Decreased	Diagnostic	Plasma	15
miR-31	Increased	Prognostic	Plasma	13
miR-93	Increased	Diagnostic	Plasma	2
miR-92a	Increased	Diagnostic	Serum/plasma/ serum/plasma	9, 16, 17, 18
miR-92a	No difference		Serum/plasma	5, 7
miR-96	Increased	Diagnostic/ Prognostic	Plasma	19
miR-96-5p	Decreased	Diagnostic	Plasma	20
miR-106a	Increased	Diagnostic/ Prognostic	Serum/plasma	4, 7
miR-139-5p	Increased	Prognostic	Serum	21
miR-139-5p	Decreased	Diagnostic	Serum	22
miR-141	Increased	Diagnostic	Plasma	19



Colorectal cancer				
miRNA	Direction of alteration	Value of biomarker	Sample	References
miR-142-5p	Increased	Diagnostic	Serum	10
miR-142a-3p	Decreased	Diagnostic	Plasma	12
miR-145	Decreased	Diagnostic/ Prognostic	Serum	4
miR-149	Decreased	Diagnostic	Plasma	20
miR-150	Decreased	Diagnostic	Whole blood	8
miR-155	Increased	Diagnostic/ prognostic	Serum	23
miR-183	Increased	Recurrence/ Prognostic	Serum	24
miR-194	Decreased	Diagnostic	Serum	3
miR-196b	Increased	Diagnostic	Serum	25
miR-199a-3p	Increased	Diagnostic	Serum	26
miR-200b	Increased	Prognostic	Plasma	13, 19
miR-203	Increased	Diagnostic/ Prognostic	Plasma/plasma/ serum	13, 19, 27
miR-210	Increased	Diagnostic	Serum	28
miR-221	Increased	Diagnostic	Whole blood	8
miR-223	Increased	Diagnostic	Plasma	18
miR-320a	Decreased	Diagnostic	Plasma	11
miR-375	Decreased	Diagnostic/ Prognostic	Serum	17
miR-376c-3p	Increased	Diagnostic/ Prognostic	Serum	10
miR-409-3p	Increased	Diagnostic	Plasma	2
miR-423-5p	Decreased	Diagnostic	Plasma	11
miR-425-5p	Increased	Diagnostic	Serum	6
miR-506	Increased	Diagnostic	Plasma	29
miR-622	Increased	Diagnostic	Serum	22
miR-760	Decreased	Diagnostic/ Prognostic	Serum	17
miR-4316	Increased	Diagnostic	Plasma	29

## REFERENCES

1. Ghanbari, Reza, et al. Simultaneous Underexpression of let-7a-5p and let-7f-5p microRNAs in Plasma and Stool Samples from Early Stage Colorectal Carcinoma: Supplementary Issue: Biomarkers for Colon Cancer. *Biomarkers in cancer* 7 (2015): BIC-S25252.
2. Wang, Shuyang, et al. A plasma microRNA panel for early detection of colorectal cancer. *International journal of cancer* 136.1 (2015): 152-161.
3. Basati, Gholam, et al. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. *Tumor biology* 37.2 (2016): 1781-1788.
4. Li, Jialu, et al. Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma. *Scientific reports* 5 (2015): 12921.
5. Faltejskova, Petra, et al. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: evidence against their usage as biomarkers in colorectal cancer. *Cancer Biomarkers* 12.4-5 (2013): 199-204.
6. Zhu, Mingxia, et al. A panel of microRNA signature in serum for colorectal cancer diagnosis. *Oncotarget* 8.10 (2017): 17081.
7. Chen, Wang-Yang, et al. The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer. *International journal of clinical and experimental pathology* 8.6 (2015): 7092.
8. Sarlinova, Miroslava, et al. miR-21, miR-221 and miR-150 are deregulated in peripheral blood of patients with colorectal cancer. *Anticancer research* 36.10 (2016): 5449-5454.
9. Uratani, Ryo, et al. Diagnostic potential of cell-free and exosomal microRNAs in the identification of patients with high-risk colorectal adenomas. *PLoS one* 11.10 (2016): e0160722.
10. Vyčtytilova-Faltejskova, Petra, et al. Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. *Carcinogenesis* 37.10 (2016): 941-950.
11. Fang, Zanxi, et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. *Journal of experimental & clinical cancer research* 34.1 (2015): 86.
12. Ghanbari, Reza, et al. Downregulation of plasma MiR-142-3p and MiR-26a-5p in patients with colorectal carcinoma. *Iranian journal of cancer prevention* 8.3 (2015).
13. Yuan, Zixu, et al. Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer. *British journal of cancer* 117.8 (2017): 1202.
14. Zhi, M. L., et al. Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis. *Genet Mol Res* 14.4 (2015): 18018-25.
15. Li, Leping, et al. The diagnostic efficacy and biological effects of microRNA-29b for colon cancer. *Technology in cancer research & treatment* 15.6 (2016): 772-779.
16. Yang, Xin, et al. MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis. *PLoS One* 9.2 (2014): e88745.
17. Elshafei, Ahmed, et al. The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: an Egyptian study. *Tumor Biology* 39.6 (2017): 1010428317705765.
18. Chang, Pi-Yueh, et al. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. *Oncotarget* 7.9 (2016): 10663.
19. Sun, Yan, et al. Examining plasma microRNA markers for colorectal cancer at different stages. *Oncotarget* 7.10 (2016): 11434.
20. Li, Jian, et al. GPC1 exosome and its regulatory miRNAs are specific markers for the detection and target therapy of colorectal cancer. *Journal of cellular and molecular medicine* 21.5 (2017): 838-847.
21. Miyoshi, Jinsei, et al. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. *Scientific Reports* 7 (2017): 43393.
22. Ng, Lui, et al. Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer. *Oncotarget* 8.16 (2017): 27393.
23. Lv, Zhong-chuan, et al. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. *Tumor Biology* 36.3 (2015): 1619-1625.
24. Yuan, Dawei, et al. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. *Cancer biology & therapy* 16.2 (2015): 268-275.
25. Xu, Chunjie, and Lei Gu. The diagnostic effect of serum miR-196b as biomarker in colorectal cancer. *Biomedical reports* 6.1 (2017): 39-45.
26. Nonaka, Ryoji, et al. Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. *Oncology reports* 32.6 (2014): 2354-2358.
27. Hur, Keun, et al. Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer. *Gut* (2015): gutjnl-2014.
28. Wang, W., et al. Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer. *European journal of cancer care* 26.4 (2017).
29. Krawczyk, Paweł, et al. Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer. *International journal of colorectal disease* 32.7 (2017): 1057-1060.

Date of issue April 2018

## Contact Information



### BioVendor – Laboratorní medicína a.s.

Karasek 1767/1, 621 00 Brno, Czech Republic  
Phone: +420 549 124 185, Fax: +420 549 211 460  
E-mail: info@biovendor.com

### BioVendor GmbH

Otto-Hahn-Straße 16, 34123 Kassel, Germany  
Phone: +49 (0)561 861 509 33, Fax: +49 (0)561 861 509 34  
E-mail: infoEU@biovendor.com

› [www.biovendor.com](http://www.biovendor.com)



### BioVendor GesmbH

Gaudenzdorfer Gürtel 43-45, 1120 Vienna, Austria  
Phone: +43 1 890 9025, Fax: +43 1 890 5163  
E-mail: infoAustria@biovendor.com

### BioVendor, LLC

128 Bingham Rd., Suite 1300, Asheville, NC 28806, USA  
Phone: +1-800-404-7807, Phone: +1-828-575-9250  
Fax: +1-828-575-9251, E-mail: infoUSA@biovendor.com



### Oxford Biosystems Ltd

184B Park House, Park Drive  
Milton Park, Abingdon, Oxfordshire  
OX14 4SR, United Kingdom  
Phone: +44 (0)1235 431390  
E-mail: sales@oxfordbiosystems.com

› [www.oxfordbiosystems.com](http://www.oxfordbiosystems.com)